DOP2001000224A - Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester. - Google Patents

Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.

Info

Publication number
DOP2001000224A
DOP2001000224A DO2001P000224A DO2001000224A DOP2001000224A DO P2001000224 A DOP2001000224 A DO P2001000224A DO 2001P000224 A DO2001P000224 A DO 2001P000224A DO 2001000224 A DO2001000224 A DO 2001000224A DO P2001000224 A DOP2001000224 A DO P2001000224A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical compositions
cholesterile
inhibitors
ester
transfer protein
Prior art date
Application number
DO2001P000224A
Other languages
English (en)
Inventor
William J Curatolo
Dwayne T Friesen
Michael J Gumbkowski
Douglas LORENZ
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22835821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2001000224(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2001000224A publication Critical patent/DOP2001000224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON ESTERES OXIGENADOS DE DERIVADOS DEL ACIDO 4-YODOFENILAMINO BENZHIDROXAMICO, CON COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE ELLOS. LA PRESENTE INVENCION TAMBIEN SE RELACIONA CON FORMAS CRISTALINAS DE ESTERES OXIGENADOS DE DERIVADOS DEL ACIDO 4-YODOFENILAMINO BENZHIDROXAINICO, CON COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE ELLOS.
DO2001P000224A 2000-08-03 2001-08-01 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester. DOP2001000224A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22327900P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
DOP2001000224A true DOP2001000224A (es) 2002-06-15

Family

ID=22835821

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001P000224A DOP2001000224A (es) 2000-08-03 2001-08-01 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.

Country Status (39)

Country Link
US (4) US7115279B2 (es)
EP (2) EP2258352B1 (es)
JP (2) JP2004505911A (es)
KR (1) KR100561572B1 (es)
CN (1) CN1458840A (es)
AP (1) AP2001002235A0 (es)
AR (1) AR030570A1 (es)
AT (1) ATE503462T1 (es)
AU (1) AU2914202A (es)
BG (1) BG107456A (es)
BR (1) BR0112828A (es)
CA (1) CA2417755A1 (es)
CR (1) CR6883A (es)
CZ (1) CZ2003224A3 (es)
DE (1) DE60144332D1 (es)
DO (1) DOP2001000224A (es)
DZ (1) DZ3391A1 (es)
EA (1) EA007013B1 (es)
EC (1) ECSP034462A (es)
EE (1) EE200300052A (es)
GT (1) GT200100156A (es)
HN (1) HN2001000175A (es)
HU (1) HUP0300676A2 (es)
IL (1) IL154017A0 (es)
IS (1) IS6688A (es)
MA (1) MA26935A1 (es)
MX (1) MXPA03001035A (es)
NO (1) NO20030506D0 (es)
NZ (1) NZ523680A (es)
OA (1) OA12350A (es)
PA (1) PA8523901A1 (es)
PE (1) PE20020271A1 (es)
PL (1) PL365168A1 (es)
SK (1) SK1032003A3 (es)
SV (1) SV2002000581A (es)
TN (1) TNSN01119A1 (es)
UY (1) UY26864A1 (es)
WO (1) WO2002011710A2 (es)
ZA (1) ZA200300869B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
IL158765A0 (en) * 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
CA2448864C (en) * 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
DE60237602D1 (de) * 2001-06-22 2010-10-21 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
EA006777B1 (ru) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
CA2474835A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2004014342A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
ES2377121T3 (es) 2003-03-17 2012-03-22 Japan Tobacco Inc. Composiciones farmacéuticas de inhibidores de CETP
CN101036636A (zh) * 2003-03-17 2007-09-19 日本烟草产业株式会社 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
MXPA06001417A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06003357A (es) * 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
EP1670765A2 (en) * 2003-09-30 2006-06-21 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
DK1670768T3 (da) * 2003-10-08 2009-11-09 Lilly Co Eli Forbindelser og fremgangsmåder til at behandle dyslipidæmi
SI1759702T1 (sl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
KR101238525B1 (ko) 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
JP5773560B2 (ja) * 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1997819A1 (de) 2007-05-25 2008-12-03 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Scopinestern
US8337835B2 (en) * 2009-04-10 2012-12-25 Washington University Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
MX2013010306A (es) 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
RU2015123632A (ru) * 2012-11-19 2017-01-10 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции ингибиторов сетр

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299641B1 (en) 1987-07-17 1992-06-10 Dow Corning Corporation A curable composition
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5093371A (en) 1990-07-02 1992-03-03 University Of Iowa Research Foundation Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5474993A (en) 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
GB2305665A (en) 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
JP3290962B2 (ja) * 1997-02-12 2002-06-10 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
ATE253565T1 (de) 1997-04-16 2003-11-15 Univ New Mexico Inhibitoren der cholesterolesterase
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
AU9297798A (en) 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JP3433417B2 (ja) * 1998-04-02 2003-08-04 トヨタ自動車株式会社 レーダ装置
CA2328703C (en) 1998-06-11 2007-10-30 Pharmacia & Upjohn Company Delavirdine tablet formulation
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
CA2345108A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
ATE296796T1 (de) 1998-09-25 2005-06-15 Monsanto Co (r)-chirale halogenierte 1-substituierte amino- (n+1)-alkanolen für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
RU2201964C2 (ru) 1999-03-08 2003-04-10 Дзе Китасато Инститьют Соединение wk-5344а и соединение wk-5344b, способ их получения и продуцирующий их штамм streptomyces sp. wk-5344 ferm bp-6668
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
AP2002002553A0 (en) * 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE60237602D1 (de) 2001-06-22 2010-10-21 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
MXPA03011935A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CN1309370C (zh) 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.

Also Published As

Publication number Publication date
CA2417755A1 (en) 2002-02-14
JP2004505911A (ja) 2004-02-26
US20070282009A1 (en) 2007-12-06
ATE503462T1 (de) 2011-04-15
EA007013B1 (ru) 2006-06-30
AU2914202A (en) 2002-02-18
EP2258352A3 (en) 2013-08-14
EP1305007B1 (en) 2011-03-30
DE60144332D1 (de) 2011-05-12
PA8523901A1 (es) 2002-04-25
PE20020271A1 (es) 2002-04-08
AR030570A1 (es) 2003-08-27
GT200100156A (es) 2002-04-23
HN2001000175A (es) 2001-10-08
EP2258352B1 (en) 2015-05-13
US20060211654A1 (en) 2006-09-21
US8197848B2 (en) 2012-06-12
CR6883A (es) 2003-11-25
SV2002000581A (es) 2002-10-24
MXPA03001035A (es) 2003-05-27
US7115279B2 (en) 2006-10-03
HUP0300676A2 (hu) 2003-08-28
BR0112828A (pt) 2003-07-01
NZ523680A (en) 2004-09-24
BG107456A (bg) 2003-09-30
EP1305007A2 (en) 2003-05-02
MA26935A1 (fr) 2004-12-20
IL154017A0 (en) 2003-07-31
ECSP034462A (es) 2003-03-31
US20020103225A1 (en) 2002-08-01
EP2258352A2 (en) 2010-12-08
NO20030506L (no) 2003-01-31
EA200300073A1 (ru) 2003-08-28
US20120277315A1 (en) 2012-11-01
US8389011B2 (en) 2013-03-05
US8048452B2 (en) 2011-11-01
WO2002011710A2 (en) 2002-02-14
AP2001002235A0 (en) 2001-09-30
JP2007314573A (ja) 2007-12-06
CZ2003224A3 (cs) 2004-02-18
KR100561572B1 (ko) 2006-03-16
WO2002011710A3 (en) 2002-05-02
ZA200300869B (en) 2004-04-16
TNSN01119A1 (fr) 2005-11-10
DZ3391A1 (fr) 2002-02-14
EE200300052A (et) 2004-12-15
IS6688A (is) 2003-01-16
SK1032003A3 (en) 2004-05-04
CN1458840A (zh) 2003-11-26
PL365168A1 (en) 2004-12-27
OA12350A (en) 2006-05-16
NO20030506D0 (no) 2003-01-31
KR20030026995A (ko) 2003-04-03
UY26864A1 (es) 2002-02-28

Similar Documents

Publication Publication Date Title
DOP2001000224A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
SV2002000563A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamicos
PA8565101A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
SV2003001103A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester pc10894
AR031129A1 (es) Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
HN1997000110A (es) Derivados del acido arilsulfoonilamino hidroxamico
HUP0302345A2 (hu) Új triazolo-pirimidin-vegyületek, ezek intermedierjei és eljárás az előállításukra
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
CY1107641T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
SE9801494D0 (sv) Novel use
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
HN2001000024A (es) Composiciones mejoradas inmunomoduladoras y neutralizantes de anticuerpos.
AR031608A1 (es) Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
ATE462779T1 (de) Nukleinsäurefreie ghost zusammensetzungen
CY1107277T1 (el) Βενζισοξαζολες
UY26848A1 (es) Esteres oxigenados de ácidos 4- yodo fenilamino benzhidroxamicos
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
NO20024679D0 (no) Krystallinsk farmasöytikum